JP2023520636A - Ｔ細胞二重特異性結合タンパク質 - Google Patents

Ｔ細胞二重特異性結合タンパク質 Download PDF

Info

Publication number
JP2023520636A
JP2023520636A JP2022555860A JP2022555860A JP2023520636A JP 2023520636 A JP2023520636 A JP 2023520636A JP 2022555860 A JP2022555860 A JP 2022555860A JP 2022555860 A JP2022555860 A JP 2022555860A JP 2023520636 A JP2023520636 A JP 2023520636A
Authority
JP
Japan
Prior art keywords
bispecific
amino acid
seq
binding
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520636A5 (https=
Inventor
パルチョウデュリー ラーフル
アール ピアース ブラッドリー
リ チン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dianthus Therapeutics Inc
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of JP2023520636A publication Critical patent/JP2023520636A/ja
Publication of JP2023520636A5 publication Critical patent/JP2023520636A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022555860A 2020-03-16 2021-03-16 Ｔ細胞二重特異性結合タンパク質 Pending JP2023520636A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990281P 2020-03-16 2020-03-16
US62/990,281 2020-03-16
PCT/US2021/022626 WO2021188590A2 (en) 2020-03-16 2021-03-16 T-cell bispecific binding proteins

Publications (2)

Publication Number Publication Date
JP2023520636A true JP2023520636A (ja) 2023-05-18
JP2023520636A5 JP2023520636A5 (https=) 2024-03-21

Family

ID=77768281

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555860A Pending JP2023520636A (ja) 2020-03-16 2021-03-16 Ｔ細胞二重特異性結合タンパク質

Country Status (7)

Country Link
US (1) US20230183344A1 (https=)
EP (1) EP4121462A4 (https=)
JP (1) JP2023520636A (https=)
CN (1) CN115667314A (https=)
AU (1) AU2021239929A1 (https=)
CA (1) CA3171709A1 (https=)
WO (1) WO2021188590A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4638505A1 (en) * 2022-12-21 2025-10-29 Erasmus University Rotterdam Medical Center Bispecific antibodies targeting cd117 and cd3
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN119874942B (zh) * 2025-03-28 2025-09-26 核欣(苏州)医药科技有限公司 一种放射性蛋白偶联药物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015121383A1 (en) * 2014-02-12 2015-08-20 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
JP2018529317A (ja) * 2015-07-31 2018-10-11 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ メソテリン及びｃｄ３に結合する二重特異性抗体構築物
JP2019504321A (ja) * 2016-01-25 2019-02-14 ジェネンテック， インコーポレイテッド Ｔ細胞依存性二重特異的抗体をアッセイするための方法
WO2019084057A2 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
WO2019084064A2 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL263466B2 (en) * 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
HRP20201779T1 (hr) * 2015-05-28 2021-01-22 Genentech, Inc. Stanični test za otkrivanje anti-cd3 homodimera
AU2016337525B2 (en) * 2015-10-16 2022-01-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
US10538579B2 (en) * 2016-08-15 2020-01-21 Board Of Regents, The University Of Texas System Bispecific pertussis antibodies
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
AU2019366960A1 (en) * 2018-10-23 2021-05-27 Regeneron Pharmaceuticals, Inc. Fc silenced antibody drug conjugates (ADCs) and uses thereof
GB201912681D0 (en) * 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015121383A1 (en) * 2014-02-12 2015-08-20 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
JP2018529317A (ja) * 2015-07-31 2018-10-11 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ メソテリン及びｃｄ３に結合する二重特異性抗体構築物
JP2019504321A (ja) * 2016-01-25 2019-02-14 ジェネンテック， インコーポレイテッド Ｔ細胞依存性二重特異的抗体をアッセイするための方法
WO2019084057A2 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
WO2019084064A2 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ONCOTARGET, vol. 8, no. 31, JPN6025006049, 2017, pages 51037 - 51049, ISSN: 0005530068 *

Also Published As

Publication number Publication date
CA3171709A1 (en) 2021-09-23
WO2021188590A2 (en) 2021-09-23
AU2021239929A1 (en) 2022-10-13
EP4121462A4 (en) 2024-04-24
CN115667314A (zh) 2023-01-31
WO2021188590A3 (en) 2022-07-21
EP4121462A2 (en) 2023-01-25
US20230183344A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
JP2023520636A (ja) Ｔ細胞二重特異性結合タンパク質
US11919970B2 (en) Antibodies and chimeric antigen receptors specific for ROR1
US11827714B2 (en) Antibodies and chimeric antigen receptors specific for CD19
US11098099B2 (en) Interleukin-2 fusion proteins and uses thereof
BR112020018927A2 (pt) Anticorpos contra proteína alfa reguladora de sinal e métodos de uso
TW201806972A (zh) 雙特異性結合蛋白
WO2019084067A1 (en) ANTI-CD117 ANTIBODIES AND METHODS OF USE
RS60305B1 (sr) Agensi koji vezuju cd123 i njihove upotrebe
JP2023516286A (ja) グリピカン－３（ｇｐｃ３）を標的化する抗体及びキメラ抗原受容体並びにその使用方法
KR20220030934A (ko) 항-gal9 면역-억제 결합 분자
WO2019084053A1 (en) COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
HK40049993A (en) Antibodies and chimeric antigen receptors specific for cd19
HK40104849A (zh) 用於诊断和治疗用途的针对lilrb1的单克隆抗体
HK40114909A (zh) 活化的肝星状细胞(hsc)的消耗及其用途
HK1240239A1 (en) Antibodies and chimeric antigen receptors specific for cd19
HK1240239B (en) Antibodies and chimeric antigen receptors specific for cd19
HK1246314B (en) Antibodies and chimeric antigen receptors specific for ror1
HK1240948B (zh) Cd123结合剂及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250819